StockNews.com Initiates Coverage on Catalent (NYSE:CTLT)

Analysts at StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

A number of other research firms have also recently issued reports on CTLT. Barclays lifted their price objective on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, July 11th. Finally, William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $58.08.

Catalent Stock Down 0.3 %

CTLT stock opened at $60.11 on Wednesday. The company has a 50 day moving average of $59.43 and a two-hundred day moving average of $57.19. The company has a market cap of $10.88 billion, a price-to-earnings ratio of -9.85, a PEG ratio of 1.88 and a beta of 1.15. Catalent has a 12-month low of $31.80 and a 12-month high of $61.20. The company has a quick ratio of 1.77, a current ratio of 2.52 and a debt-to-equity ratio of 1.35.

Insider Buying and Selling

In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Matti Masanovich sold 2,993 shares of the business’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $56.74, for a total transaction of $169,822.82. Following the transaction, the chief financial officer now owns 33,871 shares of the company’s stock, valued at $1,921,840.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The disclosure for this sale can be found here. In the last three months, insiders sold 13,409 shares of company stock valued at $782,923. Company insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Catalent

Large investors have recently added to or reduced their stakes in the company. Lindbrook Capital LLC raised its stake in shares of Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after buying an additional 208 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Catalent in the second quarter worth about $42,000. Mather Group LLC. bought a new position in Catalent during the first quarter worth about $52,000. Longfellow Investment Management Co. LLC lifted its stake in Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after purchasing an additional 305 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after purchasing an additional 212 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.